Guggenheim Maintains Buy on Eledon Pharmaceuticals, Lowers Price Target to $8
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.
Guggenheim analyst Vamil Divan maintains Eledon Pharmaceuticals (NASDAQ:ELDN) with a Buy and lowers the price target from $9 to $8.